Dabigatran

Routes
Oral (PO)
Half-Life (t½)
PO: 13h
Formula
C25H25N7O3
Molecular Weight
471.51 g/mol
PubChem CID
216210
Aliases
Pradaxa, dabigatran etexilate, BIBR 1048

Pharmacological Mechanism

Dabigatran etexilate is an oral prodrug; esterase hydrolysis in gut/liver/plasma yields active dabigatran, a reversible, competitive direct thrombin inhibitor that binds both free and fibrin-bound thrombin. Absorption from the gut requires an acidic microenvironment — hence the tartaric-acid pellet formulation and the tendency for dyspepsia. ~80% renal elimination makes creatinine clearance the dominant determinant of exposure. Specific reversal agent: idarucizumab.

Half-Life & Elimination Curve (PO: 13h)

100%50%25%12.5%0%0h0×t½13h1×t½26h2×t½39h3×t½52h4×t½65h5×t½0×t½ (0h): 100% remaining (~0.142 mg/L)1×t½ (13h): 50% remaining (~70.8 µg/L)2×t½ (26h): 25% remaining (~35.4 µg/L)3×t½ (39h): 12.5% remaining (~17.7 µg/L)4×t½ (52h): 6.3% remaining (~8.85 µg/L)5×t½ (65h): 3.1% remaining (~4.42 µg/L)
Plasma (PO)t½ Decay (13h)Effect Site (ke0)
  • 0×t½0h100% (0.142 mg/L)
  • 1×t½13h50% (70.8 µg/L)
  • 2×t½26h25% (35.4 µg/L)
  • 3×t½39h12.5% (17.7 µg/L)
  • 4×t½52h6.3% (8.85 µg/L)
  • 5×t½65h3.1% (4.42 µg/L)
Elimination t½13h (PO)
Rate Constant (ke)0.0533 h⁻¹
Time to Peak (Tmax)3.98h
Est. Peak (Cmax)0.142 mg/L
Clearance (CL)3.2 L/h
97% Washout (5×t½)65h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References